MedPath

A study to evaluate the efficacy of Balaguduchyadi basti on the level of micronutrients.

Phase 2
Conditions
Health Condition 1: R70-R79- Abnormal findings on examination of blood, without diagnosisHealth Condition 2: K00-K95- Diseases of the digestive systemHealth Condition 3: M00-M99- Diseases of the musculoskeletal system and connective tissue
Registration Number
CTRI/2023/08/056473
Lead Sponsor
Ayurvedic and Unani Tibbia college and hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patient with any of micronutrient deficiency- Vit D, Iron, Calcium, Vit B-12, Magnesium,Zinc, Folic Acid- Requiring any External panchakarma therapy, Independent of Sex, eating habits or socio- economic status

Exclusion Criteria

Patients who are contraindicated for niruha basti and anuvasan basti like skin disorders, ascites, intestinal perforation ,intestinal obstruction etc. will not be included in the trial (Group A)

Patients with comorbid condition such as hypertension(systolic >150mmhg and diastolic >100 mmhg despite anti hypertensive medication) and diabetes mellitus (having HBA1c >7%) despite anti diabetic medication)

Pregnant women and lactating mothers

Patient suffering from major illness such as malignancy, HIV and TB

Patient requiring emergency treatment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of the effect of basti on objective parameters of Vitamin D, Vitamin B12, Serum iron, Serum zinc, Serum calcium, Serum magnesium, and Serum folic acid. <br/ ><br>Timepoint: Vitamin D, Vitamin B12, Serum <br/ ><br>iron, Serum zinc, Serum calcium, Serum magnesium, and Serum folic acid. <br/ ><br>[Time frame:45th day]
Secondary Outcome Measures
NameTimeMethod
1.Assessment of quality of life using the questionnaire of WHO - QOL BREF Scale. <br/ ><br>2.Assessment of absorption of Balaguduchyadi basti in the systemic circulation.Timepoint: 1.Questionnaire of WHO-QOL Bref Scale.[Time frame:45th day] <br/ ><br>2.HPLC <br/ ><br>[Time frame: between 1st to 2nd day] <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath